|
|
|
| Correlation between the ultrasonography findings of non-mass-like breast cancer and its pathologic features |
| ZHANG Hai-li, LIU Xiao-jing, PANG Hui-yan |
| Department of Ultrasound, Jiangsu Provincial Government Hospital, Nanjing 210000, China |
|
|
|
|
Abstract Objective: To preliminarily explore the relationship between the ultrasonography findings of non-mass-like breast cancer and its pathologic features. Methods: Sixty-nine female patients with 69 pathologically confirmed non-mass-like breast cancers were enrolled in this study. The ultrasonography features of all the lesions were classified as four types: “duct dilatation”, “sheet low echo”, “local architecture distortion”, and “mixed change.” Pearson Chi-Square test and Fisher’s exact test were performed to compare pathologic features of different ultrasonography types of non-mass-like breast cancer. Results: The proportion of ductal carcinoma in situ(DCIS) in the type of “Duct dilatation” was 81.8%, and significantly larger than the other three types(P<0.001). No DCIS existed in the type of “mixed change” whose histologic type was all invasive cancer. The type of “local architecture distortion” had only one DCIS(9.1%). The positive rates of human epidermal growth factor receptor-2(HER-2) in the type of “duct dilatation”(72.7%) and “mixed change”(68.8%) were higher than in the type of “sheet low echo”(40.0%) and “local architecture distortion”(27.3%) and the difference was statistically significant on the whole(P=0.035). Axillary lymph node metastases were more commonly seen in the type of“mixed change”(50.0%) than in the type of “duct dilatation”(0.0%), “sheet low echo”(26.7%), and “local architecture distortion”(27.3%) and the overall different was statistically significant(P=0.019). Conclusion: Ultrasonography types of non-mass-like breast cancer have some correlation with histologic type, HER-2 expression and axillary lymph node metastasis.
|
|
Received: 26 December 2016
|
|
|
|
|
|
[1]Uematsu T. Non-mass-like lesions on breast ultrasonography: a systematic review[J]. Breast Cancer, 2012, 19(4): 295-301.
[2]Ko KH, Hsu HH, Yu JC, et al. Non-mass-like breast lesions at ultrasonography: feature analysis and BI-RADS assessment[J]. Eur J Radiol, 2015, 84(1): 77-85.
[3]Wang ZL, Li N, Li M, et al. Non-mass-like lesions on breast ultrasound: classification and correlation with histology[J]. La Radiologia Medica, 2015, 120(10): 905-910.
[4]张晓红，朱丹茹，齐东，等. 42例非肿块型乳腺恶性肿瘤的超声分析[J]. 中外医疗，2015，（7）：175-176.
[5]Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. Arch Pathol Lab Med, 2010, 134(6): 907-922.
[6]Gwak YJ, Kim HJ, Kwak JY, et al. Ultrasonographic detection and characterization of asymptomatic ductal carcinoma in situ with histopathologic correlation[J]. Acta Radiol, 2011, 52(4): 364-371.
[7]Zhang W, Gao EL, Zhou YL, et al. Different distribution of breast ductal carcinoma in situ, ductal carcinoma in situ with microinvasion, and invasion breast cancer[J]. World J Surg Oncol, 2012, 10: 262.
[8]孙江宏，国飞，姜丹，等. 非肿块型乳腺导管癌数字化乳腺X线摄影表现形式与病理类型的相关性分析[J]. 临床外科杂志，2015，（1）：24-26.
[9]Hoque A, Sneige N, Sahin AA, et al. Her-2/neu gene amplification in ductal carcinoma in situ of the breast[J]. Cancer Epidemiol Biomarkers Prevent, 2002, 11(6): 587-590.
[10]Mylonas I, Makovitzky J, Jeschke U, et al. Expression of Her2/neu, steroid receptors(ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ(DCIS) Versus invasive breast cancer alone[J]. Anticancer Res, 2005, 25(3A): 1719-1723.
[11]Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine[J]. Oncologist, 2009, 14(4): 320-368. |
|
|
|
2017, Vol. 28 
